Columbia biomedical engineers have designed a novel probiotic strain that after a single dose can seek out solid tumours and safely deliver immune checkpoint inhibitors, resulting in tumour regression of treated and untreated cancer lesions.

Researchers at Columbia Engineering have engineered probiotics to safely deliver immunotherapies within tumours.

These include nanobodies against two proven therapeutic targets--PD-L1 and CTLA-4.

The drugs are continuously released by bacteria and continue to attack the tumour after just one dose, facilitating an immune response that ultimately results in tumour regression.

The versatile probiotic platform can also be used to deliver multiple immunotherapies simultaneously, enabling the release of effective therapeutic combinations within the tumour for more difficult-to-treat cancers like colorectal cancer.

The study is published today in Science Translational Medicine.

Antibodies that target immune checkpoints, PD-L1 and CTLA-4, have revolutionised cancer immunotherapy treatments, achieving success in a subset of cancers.

However, systemic delivery of these antibodies can also cause substantial side effects with high percentages of patients reporting adverse reactions.

Furthermore, although combinations of these therapies are more effective than single therapy regimens, they also produce severe toxicities, sometimes leading to drug discontinuation.

The team, led by Tal Danino, assistant professor of biomedical engineering, aimed to address these challenges.

"We wanted to engineer a safe probiotic vehicle capable of delivering immune checkpoint therapies locally to minimise side effects," says Danino, who is also a member of the Herbert Irving Comprehensive Cancer Center and Data Science Institute.

"We also wanted to broaden the versatility of the system by producing a range of immunotherapeutic combinations, including cytokines that could further elicit antitumour immunity, but are otherwise difficult to systemically deliver because of toxicity concerns."

Bacterial cancer therapy is not a new idea: in the 1890s, William Coley, a New York City surgeon, demonstrated that injection of live streptococcal organisms into cancer patients could shrink tumours.

While his method was never widely adopted because radiotherapy was discovered around the same time and antibiotics were not widely available, physicians have been using a tuberculosis vaccine, BCG, as a therapy for bladder cancer for decades.

The Danino lab has pioneered engineered bacteria for cancer therapy, developing methods to characterise different strains of bacteria, therapeutics, and genetic control circuits to effectively release cancer drugs.

In this most recent study, led by PhD student Candice Gurbatri, they sought to engineer a translational therapeutic platform that improved upon a previous lysis circuit.

Using computational modelling, they first scanned multiple parameters to find the optimal circuit variants to maximise drug release within the tumour.

This led to the integration of the circuit into the genome of a widely-used probiotic strain--E.coli Nissle 1917--resulting in a strain they call "SLIC," or the synchronised lysing integrated circuit.

This SLIC probiotic strain is naturally capable of finding and growing within tumours in the body, but the genomic integration of this circuit ensures greater stability of the system and higher levels of therapeutic release.

"We have demonstrated that the engineered bacteria remain functional and localised within the tumour as the bacteria grow in mice for at least two weeks after treatment, preventing the microbes from affecting healthy tissue," says Gurbatri.

Testing in mouse models further demonstrated that unlike previous iterations of the circuit, SLIC was able to clear tumours after a single dose, adding to its translational potential.

Because the circuit is integrated into the genome, the stability of the platform greatly increases, thus negating the need for multiple injections of bacteria.

The research team used this probiotic delivery system to release nanobodies blocking PD-L1 and CTLA-4 within tumours in mouse models of lymphoma and colorectal cancer.

It is already known that tumours express these checkpoints to stop the immune system, specifically T cells, from functioning properly.

The goal of blocking PD-L1 and CTLA-4 is to remove the "brakes" and enable T cells to attack the cancer.

A direct comparison to clinically relevant antibodies against the same target showed that their probiotic therapy was more effective, leading to complete tumour regression and prevention of metastatic formation in early and late-stage mouse models of lymphoma.

Leveraging the versatility of this system, the researchers sought to treat more difficult cancers, like colorectal, that have been less responsive to traditional immunotherapies.

In this additional model, they paired the immune checkpoint nanobodies with a cytokine to further stimulate the immune system.

A single dose of this probiotic cocktail resulted in tumour regression with no observed side-effects.

Says Gurbatri, "We showed that a triple combination of immunotherapies could effectively reduce tumour growth in a cancer that is generally less responsive to immunotherapy. We've demonstrated that one dose of our probiotic therapy results in continuous localised drug release and clearance of the bacteria population once tumours have cleared. These elements could be particularly beneficial in a clinical setting, where patients want and need minimally invasive and self-sustained therapies."

Source: Columbia Engineering